Despite macroscopically radical surgery and combined adjuvant chemoradiation recurrence of malignant glioma remains a certainty. About 80% of patients experience a tumor recurrence within 2 cm of the resection margin. Only a select group of patients with recurrent malignant gliomas are candidates for reoperation, but in spite of further adjuvant therapy, long-term survival is rare. The GliaSite® RTS was developed in an attempt to allow an additional radiation dose to be delivered in a way that maximizes the patient's quality of life while delivering a radiation dose to the tissue at greatest risk of recurrence. This study reports our experience with GliaSite® on 12 patients with recurrent high grade gliomas. The median radiation dose delivered was 46.5 Gy (range 45-60 Gy) to an average depth of 1 cm from the surgical cavity wall. Mild side effects post lotrex infusion were easily managed with drug therapy. One case of late symptomatic radiation necrosis was pathologically documented and a second case radiologically suspected. At the time of this analysis (median follow up 8.4 months, range 1-14 months) two patients died after 12 months from GliaSite® treatment for disease progression. These preliminary data need to be confirmed by a larger patient population with more information on the progression-free survival and overall survival. Our preliminary results confirm that brachytherapy treatment with GliaSite® is safe, improves quality of life and reduces the radiation adverse effects versus external beam radiotherapy.
|Number of pages||9|
|Publication status||Published - Dec 2007|
- High grade gliomas
ASJC Scopus subject areas